Literature reviews  >  Articles for review > Bianchi A et al. PreservCyt transport... 

 

About SDI
Mission
Diagnostic
Priorities
Workplan
Activities
Newsletters
Grants
Publications
Journal articles
Guidelines
Manuals
Reports
Literature reviews
Contact us

C. trachomatis can be detected in PreservCyt transport medium by the COBAS Amplicor CT/NG test.

PreservCyt transport medium used for the ThinPrep test is a suitable medium for detection of Chlamydia trachomatis by the COBAS Amplicor CT.NG test: results of a preliminary study and future implications.
Bianchi A, Moret F, Desrues JM, Champenois T, Dervaux Y, Desvouas O, Oursin A, Quinzat D, Dachez R, Bathelier C, Ronsin C.  
Journal of Clinical Microbiology
2002;40:1740-1754.

 

Summary:

Question
Can the automated COBAS Amplicor CT/NG test detect C. trachomatis in cervical specimens collected in PreservCyt transport medium?

Design
This paper describes a prospective study to evaluate the ability of the automated PCR COBAS Amplicor CT/NG test to detect C. trachomatis in PreservCyt transport medium used for the ThinPrep Pap test

Participants
Consenting women, aged 15 to 25 years, who presented for Pap screening at different general practitioners, dermatologists, and family planning centers in France were studied. One thousand PreservCyt samples were selected according to the following criteria: 1) they showed normal cytology, and 2) were from patients who showed no clinical sign of urogenital infection, including genital or pelvic pain, dysuria, and urethritis.

Description of Tests and Diagnostic Standard
PreservCyt (Cytyc Corporation, Boxborough, MA) specimens were first used to make ThinPrep slides (Cytyc Corporation) for cytological evaluation and then tested within one week of collection by the COBAS Amplicor CT/NG PCR assay (Roche Diagnostic Systems, Meylan, France) for the presence of C. trachomatis. Before testing, 2 ml of sample was centrifuged, the pellet was suspended in 1 ml of 2-sucrose-phosphate transport medium (2SP, Roche Diagnostic Systems), and the samples were analyzed according to the manufacturer's instructions. To confirm positive results, patients whose PreservCyt samples were positive by Amplicor (absorbance >0.8) were asked to give a new endocervical swab specimen that was collected and tested by standard Amplicor CT/NG PCR assay procedures. Positive PreservCyt specimens were stored at 15 to 20oC for 6 weeks and retested by the Amplicor assay at 2, 4, and 6 weeks after collection.

Main Outcome Measures
The sensitivity of detection of titered, purified C. trachomatis elementary bodies in PreservCyt medium compared with that of 2SP transport medium in a dilution assay, and the results of the Amplicor assay on fresh and stored PreservCyt specimens were determined.

Main Results
The in vitro sensitivity assay showed that 1 IFU/ml of C. trachomatis elementary bodies was detected in duplicate from 2SP medium in 3 of 4 attempts, compared to 1 of 4 attempts when assayed from PreservCyt medium. Both collection media gave consistently positive results for duplicate assays performed 4 times on samples seeded with 10 IFU/ml of elementary bodies. C. trachomatis was detected in 22 (2.2%) of the 1000 clinical PreservCyt specimens. All 22 of these samples were positive on repeat assay of the same PreservCyt sample for up to 6 weeks. No inhibition was observed in any of the samples tested. All 9 of the 22 positive patients who agreed to be retested with an endocervical swab placed in 2SP were positive for the Amplicor test.

Authors' Conclusions
PreservCyt transport medium is a suitable collection medium for routine screening of C. trachomatis infections with the COBAS Amplicor CT/NG test.

Source of funding: Cytyc France SARL, and Roche Diagnostics, Meylan, France

For correspondence: Christophe Ronsin, L. C. L. Service de Biologie Moleculaire, 78 Avenue de Verdun, BP 110, 94208 Ivry sur Seine, France. E-mail address: c.ronsin@lablcl.com.

expert review

   

about SDI | newsletters | grants | publications | literature reviews

WHO Home - WHO Search - TDR Home - SDI Home - SDI Contact us
(c) WHO/OMS 2001